

PATENT

Attorney Docket No. 7675.0001-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
 Christer OWMAN)
)
 Application No.: 09/893,512) Group Art Unit: 1647
)
 Filed: June 29, 2001) Examiner: R. LANDSMAN
)
 For: HEPTAHELIX RECEPTOR AND)
 ITS USE AS LEUKOTRIENE B4)
 RECEPTOR)

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

DECLARATION UNDER 37 C.F.R. § 1.131

Sir:

I, Christer Owman, declare that:

1. I am the sole named applicant of the above-identified application and am the sole inventor of the subject matter described and claimed therein.
2. On information and belief, Yokomizo, T., *et al.* (*Nature* 387:620-624, June 5, 1997), has been cited as prior art under 35 U.S.C. § 102(a) against claims of the above-identified application.
3. Prior to June 5, 1997, which is the publication date of Yokomizo *et al.*, I had completed, in Sweden, the invention as described and claimed in the above-identified application.

FINNEGAN
 HENDERSON
 FARABOW
 GARRETT &
 DUNNER LLP

1300 I Street, NW
 Washington, DC 20005
 202.408.4000
 Fax 202.408.4400
 www.finnegan.com

Attorney Docket No. 7675.0001-03
Application No. 09/893,512

4. Evidence supporting the fact declared in paragraph 3 is as follows:

On October 15, 1996, I published a manuscript describing clone Lyme21-9, which contains the complete nucleotide sequence of the CMKRL1 gene. Expression of the Lyme21-9 clone resulted in production of the CMKRL1 protein, as assayed by mRNA expression. See "Cloning of cDNA Encoding a Putative Chemoattractant Receptor", *Genomics* 37(2):187-194; attached as Exhibit A.)

5. The publication referred to in paragraph 4 shows that I had completed the invention claimed in the above-identified application before the publication date of Yokomizo *et al.*

6. All statements made herein of my knowledge are true. All statements made herein on information and belief are believed to be true. All statements made herein were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements might jeopardize the validity of this application or any patent issuing therefrom.

Date:

Sept. 10, 2003


By:



Christer Owman, Ph.D., M.D.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



PATENT
Attorney Docket No. 07675.0001-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent Application of:)
Christer OWMAN)
Application No.: 09/893,512) Group Art Unit: 1647
Filed: June 29, 2001) Examiner: R. LANDSMAN
For: HEPTAHELIX RECEPTOR AND)
ITS USE AS LEUKOTRIENE B4)
RECEPTOR)

Assistant Commissioner for Patents
Washington, D.C. 20231

DECLARATION PURSUANT TO 37 C.F.R. § 1.804

I, Bjorn Olde, declare that:

1. I am a citizen of Sweden, residing at Vastergaten 6, SE-222, 29 Lund, Sweden.
2. I have read and understand the present U.S. patent application, including the claims.
3. I have been professionally associated with Dr. Christer Owman, the inventor and applicant for this application, since October, 1994.
4. On information and belief, the Lyme21-9 clone disclosed in the present application, as originally filed, has been deposited at the ATCC, and assigned Accession No. PTA-4543.
5. The Lyme21-9 clone originally disclosed in the present application, as filed, is the same biological material that was deposited at the ATCC.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Attorney Docket No. 07675.0001-03
Application No. 09/893,512

6. All statements made herein of my knowledge are true. All statements made herein on information and belief are believed to be true. All statements made herein were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements might jeopardize the validity of this application or any patent issuing therefrom.

Date: 2003-04-07

By:

Bjorn Olde, Ph.D.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com